Pivotal readout

Elafibranor normalizes ALP in most PBC patients in phase 3 ELSPIRE

In ELSPIRE, which enrolled primary biliary cholangitis patients with only mildly raised alkaline phosphatase, 85.3% on elafibranor reached normal ALP by week 52 versus 23.3% on placebo, and the drug was well tolerated. The data were shown at this year's AASLD liver congress and are being filed with regulators.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of elafibranor entering a liver cell and switching on PPAR-alpha and PPAR-delta proteins, which pair with a partner protein on DNA and turn down the making of bile acid from cholesterol.
Elafibranor: switching on PPAR-alpha and PPAR-delta. Watch the mechanism animation on the elafibranor page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call